Press release 📈 Stocks 🌍 United States

Madrigal Pharmaceuticals Faces Investor Probe Following Whistleblower Claims

Law firm Kessler Topaz Meltzer & Check is investigating Madrigal Pharmaceuticals after a whistleblower alleged the company suppressed safety data for its Rezdiffra drug, triggering an 8% stock decline.

📅 November 7, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 1 Bearish, 0 Neutral. Strongest signal: MDGL ↓ 6/10 (70% confidence).

📊 Affected Assets (1)

MDGL

Bearish 🤖 70%

📅 Short-term 🌍 US · Explicit

A law firm is investigating securities-law violations after Madrigal disclosed on November 3, 2026 that a former SVP filed a whistleblower complaint on October 9, 2026 alleging suppression of adverse liver-injury data and unreproducible efficacy results for Rezdiffra, the company's only approved drug. The stock already fell over 8% on the disclosure, and a formal class-action investigation adds continuing legal and reputational pressure. Some negative news is already priced in, which limits further downside from this announcement alone.

Catalysts

▼ Whistleblower complaint by former Head of Clinical Development disclosed November 3, 2026, alleging suppressed liver-injury data for Rezdiffra
▼ Stock drop of over 8% following the disclosure

Risk Factors

▲ The 8% drop already occurred, so the investigation itself may add only limited further pressure
▲ The investigation is preliminary and does not yet constitute a filed lawsuit or regulatory action

▼ Show FAQ (2) ▲ Hide FAQ

Why did Madrigal's stock fall?

The company disclosed on November 3, 2026 that a former Senior VP and Head of Clinical Development filed a whistleblower complaint on October 9, 2026, alleging Madrigal suppressed adverse liver-injury data and presented efficacy results for its only approved drug, Rezdiffra, that could not be reconciled with source data. The stock fell over 8% on the news.

What does the law firm investigation mean for shareholders?

Kessler Topaz Meltzer & Check is investigating potential federal securities-law violations on behalf of investors who bought Madrigal securities and suffered significant losses. Such investigations can lead to a securities-fraud class action, which may prolong uncertainty around the stock.

🎯 Key Takeaways

Madrigal Pharmaceuticals is under investigation for potential federal securities-law violations.
A former SVP alleges the company suppressed adverse liver-injury data and manipulated efficacy results for its only approved drug, Rezdiffra.
The company's stock price fell more than 8% following the disclosure of the whistleblower complaint on November 3, 2026.

📝 Executive Summary

Kessler Topaz Meltzer & Check, LLP has launched an investigation into Madrigal Pharmaceuticals following allegations of suppressed clinical data. The probe stems from a whistleblower complaint filed by a former executive, which claims the company concealed adverse liver-injury findings and manipulated efficacy results for its flagship drug, Rezdiffra. Madrigal shares dropped over 8% following the initial disclosure of these allegations in the company's recent quarterly report.

❓ FAQ

Why is Madrigal Pharmaceuticals under investigation?

The investigation follows a whistleblower complaint from a former Senior VP alleging that Madrigal suppressed adverse liver-injury data and presented unreproducible efficacy results for its Rezdiffra drug.

What is the potential impact on investors?

Law firm Kessler Topaz Meltzer & Check is evaluating potential securities-law violations on behalf of investors who suffered losses, which could lead to a formal class-action lawsuit.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article